Next Article in Journal
The Protective Role of Sulfated Polysaccharides from Green Seaweed Udotea flabellum in Cells Exposed to Oxidative Damage
Next Article in Special Issue
Investigation of the Anti-Prostate Cancer Properties of Marine-Derived Compounds
Previous Article in Journal
Recent Synthesis and Discovery of Brefeldin A Analogs
Previous Article in Special Issue
A Potential Adjuvant Agent of Chemotherapy: Sepia Ink Polysaccharides
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Mar. Drugs 2018, 16(4), 134; https://doi.org/10.3390/md16040134

A Low Molecular Weight Protein from the Sea Anemone Anemonia viridis with an Anti-Angiogenic Activity

1
Aix-Marseille University (AMU), Université d’Avignon, Centre National de la Recherche Scientifique (CNRS), Institut de la Recherche et du Développement (IRD), Institut Méditerranéen de Biologie et d’Ecologie. CNRS UMR 7263 IRD 237 Faculté de Pharmacie, 27 Bd Jean Moulin, 13385 Marseille, France
2
AMU, CNRS, Institut de Neurophysio Pathologie, 13385 Marseille, France
3
AMU, Institut National de la Santé Et de la Recherche Scientifique, 13385 Marseille, France
4
AMU, CNRS Formation de Recherche 3479, Institut de Microbiologie de la Méditerranée, Plateforme Protéomique, 31 Chemin Joseph Aiguier, 13402 Marseille, France
*
Author to whom correspondence should be addressed.
Received: 16 March 2018 / Revised: 6 April 2018 / Accepted: 12 April 2018 / Published: 19 April 2018
(This article belongs to the Collection Marine Compounds and Cancer)
View Full-Text   |   Download PDF [12488 KB, uploaded 3 May 2018]   |  

Abstract

Sea anemones are a remarkable source of active principles due to a decentralized venom system. New blood vessel growth or angiogenesis is a very promising target against cancer, but the few available antiangiogenic compounds have limited efficacy. In this study, a protein fraction, purified from tentacles of Anemonia viridis, was able to limit endothelial cells proliferation and angiogenesis at low concentration (14 nM). Protein sequences were determined with Edman degradation and mass spectrometry in source decay and revealed homologies with Blood Depressing Substance (BDS) sea anemones. The presence of a two-turn alpha helix observed with circular dichroism and a trypsin activity inhibition suggested that the active principle could be a Kunitz-type inhibitor, which may interact with an integrin due to an Arginine Glycin Aspartate (RGD) motif. Molecular modeling showed that this RGD motif was well exposed to solvent. This active principle could improve antiangiogenic therapy from existing antiangiogenic compounds binding on the Vascular Endothelial Growth Factor (VEGF). View Full-Text
Keywords: sea anemone; drug discovery; cancer; antiangiogenic; endothelial cells; RGD motif; kunitz type inhibitor sea anemone; drug discovery; cancer; antiangiogenic; endothelial cells; RGD motif; kunitz type inhibitor
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Share & Cite This Article

MDPI and ACS Style

Loret, E.P.; Luis, J.; Nuccio, C.; Villard, C.; Mansuelle, P.; Lebrun, R.; Villard, P.H. A Low Molecular Weight Protein from the Sea Anemone Anemonia viridis with an Anti-Angiogenic Activity. Mar. Drugs 2018, 16, 134.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top